481 related articles for article (PubMed ID: 24746000)
1. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
[TBL] [Abstract][Full Text] [Related]
3. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
4. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
[TBL] [Abstract][Full Text] [Related]
5. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
6. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.
Uzun S; Djamin RS; Kluytmans J; Van't Veer NE; Ermens AA; Pelle AJ; Mulder P; van der Eerden MM; Aerts J
Trials; 2012 Jun; 13():82. PubMed ID: 22682323
[TBL] [Abstract][Full Text] [Related]
7. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
Kobbernagel HE; Buchvald FF; Haarman EG; Casaulta C; Collins SA; Hogg C; Kuehni CE; Lucas JS; Moser CE; Quittner AL; Raidt J; Rosthøj S; Sørensen AL; Thomsen K; Werner C; Omran H; Nielsen KG
Lancet Respir Med; 2020 May; 8(5):493-505. PubMed ID: 32380069
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Watz H; Barnacle H; Hartley BF; Chan R
Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
[TBL] [Abstract][Full Text] [Related]
11. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
Vermeersch K; Gabrovska M; Deslypere G; Demedts IK; Slabbynck H; Aumann J; Ninane V; Verleden GM; Troosters T; Bogaerts K; Brusselle GG; Janssens W
Int J Chron Obstruct Pulmon Dis; 2016; 11():687-96. PubMed ID: 27099485
[TBL] [Abstract][Full Text] [Related]
12. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Goudie AR; Lipworth BJ; Hopkinson PJ; Wei L; Struthers AD
Lancet Respir Med; 2014 Apr; 2(4):293-300. PubMed ID: 24717626
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial.
Brusselle GG; Vanderstichele C; Jordens P; Deman R; Slabbynck H; Ringoet V; Verleden G; Demedts IK; Verhamme K; Delporte A; Demeyere B; Claeys G; Boelens J; Padalko E; Verschakelen J; Van Maele G; Deschepper E; Joos GF
Thorax; 2013 Apr; 68(4):322-9. PubMed ID: 23291349
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
15. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
[TBL] [Abstract][Full Text] [Related]
16. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.
Gibson PG; Yang IA; Upham JW; Reynolds PN; Hodge S; James AL; Jenkins C; Peters MJ; Marks GB; Baraket M; Powell H; Taylor SL; Leong LEX; Rogers GB; Simpson JL
Lancet; 2017 Aug; 390(10095):659-668. PubMed ID: 28687413
[TBL] [Abstract][Full Text] [Related]
17. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.
Goyal V; Grimwood K; Ware RS; Byrnes CA; Morris PS; Masters IB; McCallum GB; Binks MJ; Smith-Vaughan H; O'Grady KF; Champion A; Buntain HM; Schultz A; Chatfield M; Torzillo PJ; Chang AB
Lancet Respir Med; 2019 Sep; 7(9):791-801. PubMed ID: 31427252
[TBL] [Abstract][Full Text] [Related]
19. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M
Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830
[TBL] [Abstract][Full Text] [Related]
20. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
